• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Coegin Pharma

3.33 SEK-1.19 %10.7. klo 18.25
Less than 1K followers

COEGIN

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.19 %
-10.00 %
-11.44 %
-22.38 %
-25.00 %
-1.77 %
-61.64 %
-90.58 %
-89.53 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Read more
Market cap
95.21M SEK
Turnover
33.17K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22.7.
2026

Extraordinary general meeting '26

19.8.
2026

Interim report Q2'26

18.11.
2026

Interim report Q3'26

Regulatory press release25.06.2026 klo 19.46

Notice of extraordinary general meeting in Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release25.06.2026 klo 19.45

Coegin Pharma Announces a Directed Issue of Approx. SEK 6.3 Million and Secures Capital Facility Providing Access to SEK 16 Million

Coegin Pharma
Press release16.06.2026 klo 10.30

Coegin Pharma receives highly encouraging user feedback from Hårklinikken

Coegin Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release15.06.2026 klo 10.00

Coegin Pharma enters distribution agreement with LYKO for launch of first VEXIENNE® Follicopeptide® product

Coegin Pharma
Press release02.06.2026 klo 15.30

Coegin Pharma provides NPP-4 development update - INCI registration filed and commercialization preparations on track.

Coegin Pharma
Regulatory press release21.05.2026 klo 12.00

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release21.05.2026 klo 10.45

Coegin Pharma AB publishes its interim report for the first quarter of 2026

Coegin Pharma
Press release20.05.2026 klo 10.30

Coegin Pharma's partner Mercapharm prepares major commercial launch of Follicopeptide® in Poland

Coegin Pharma
Regulatory press release29.04.2026 klo 15.00

Coegin Pharma AB publishes Annual Report for 2025

Coegin Pharma
Regulatory press release20.04.2026 klo 10.20

Notice of annual general meeting in Coegin Pharma AB (publ)

Coegin Pharma
Press release16.04.2026 klo 15.53

Coegin Pharma expands commercial strategy with own-brand distribution model - launches VEXIENNE®

Coegin Pharma
Press release26.03.2026 klo 15.25

Coegin Pharma's management acquires shares in the company

Coegin Pharma
Press release04.03.2026 klo 15.30

Coegin Pharma receives first purchase order for new scalp serum

Coegin Pharma
Press release02.03.2026 klo 12.30

Coegin Pharma accelerates Follicopeptide® portfolio expansion with a new high-performance scalp serum

Coegin Pharma
Regulatory press release26.02.2026 klo 15.30

Coegin Pharma AB (publ) publishes its year-end report for 2025

Coegin Pharma
Regulatory press release19.02.2026 klo 19.40

Coegin Pharma carries out directed issues totalling approx. SEK 12.1 million and strengthens the Company's liquidity position

Coegin Pharma
Press release02.01.2026 klo 10.30

Coegin Pharma provides an operational and strategic update

Coegin Pharma
Press release22.12.2025 klo 14.30

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Coegin Pharma
Press release19.12.2025 klo 10.25

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Coegin Pharma
Press release12.12.2025 klo 12.50

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Coegin Pharma